Search our Database of Scientific Publications and Authors

I’m looking for a

    8522 results match your criteria Psoriatic Arthritis

    1 OF 171

    Using Patient Feedback to Optimize the Design of a Certolizumab Pegol Electromechanical Self-Injection Device: Insights from Human Factors Studies.
    Adv Ther 2017 Dec 8. Epub 2017 Dec 8.
    UCB Pharma, Bulle, Switzerland.
    Introduction: We incorporated patient feedback from human factors studies (HFS) in the patient-centric design and validation of ava®, an electromechanical device (e-Device) for self-injecting the anti-tumor necrosis factor certolizumab pegol (CZP).

    Methods: Healthcare professionals, caregivers, healthy volunteers, and patients with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or Crohn's disease participated in 11 formative HFS to optimize the e-Device design through intended user feedback; nine studies involved simulated injections. Formative participant questionnaire feedback was collected following e-Device prototype handling. Read More

    KIF3A and IL-4 are disease-specific biomarkers for psoriatic arthritis susceptibility.
    Oncotarget 2017 Nov 8;8(56):95401-95411. Epub 2017 Sep 8.
    Molecular Genetics Laboratory UILDM, Santa Lucia Foundation, Rome, Italy.
    To date, the genes associated with Psoriatic Arthritis (PsA) are principally involved in inflammation, immune response and epidermal differentiation, without any information about the relationship between disease and bone metabolism genes. Our work was focused on 5q31 locus, which contains several genetic variants significantly associated with PsA. The study involved 1526 subjects (500 PsA, 426 PsV, 600 controls). Read More

    Consensus on the management of patients with psoriatic arthritis in a dermatology setting.
    J Eur Acad Dermatol Venereol 2017 Dec 8. Epub 2017 Dec 8.
    Department of Medicine, Section of Dermatology and Venereology, University of Verona.
    Background: Psoriatic arthritis (PsA) is a chronic inflammatory disease associated with psoriasis (PsO). Early diagnosis and prompt therapeutic intervention are crucial for limiting PsA progression and prevention of disability. Dermatologists are in a privileged position to detect early PsA. Read More

    C5a and C5aR are elevated in joints of rheumatoid and psoriatic arthritis patients, and C5aR blockade attenuates leukocyte migration to synovial fluid.
    PLoS One 2017 8;12(12):e0189017. Epub 2017 Dec 8.
    The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Frederiksberg, Denmark.
    Complement activation correlates to rheumatoid arthritis disease activity, and increased amounts of the complement split product C5a is observed in synovial fluids from rheumatoid arthritis patients. Blockade of C5a or its receptor (C5aR) is efficacious in several arthritis models. The aim of this study was to investigate the role of C5a and C5aR in human rheumatoid arthritis and psoriatic arthritis-both with respect to expression and function. Read More

    Use of biological drugs in patients with psoriasis and psoriatic arthritis in Italy: Results from the PSONG survey.
    Dermatol Ther 2017 Dec 7. Epub 2017 Dec 7.
    Humanitas Clinical and Research Center, Skin Pathology Lab, Rozzano-Milan, Italy.
    This Italian multicenter retrospective study compared the drug survival and efficacy of different anti-TNF agents in psoriasis (PsO) and psoriatic arthritis (PsA) patients. A database of PsO/PsA patients treated with adalimumab, etanercept, and infliximab from May 2013 to May 2014 was analyzed. PASI 75, 90, and 100 was calculated at each time point to evaluate efficacy. Read More

    Magnetic resonance imaging (MRI) of feet demonstrates subclinical inflammatory joint disease in cutaneous psoriasis patients without clinical arthritis.
    Clin Rheumatol 2017 Dec 4. Epub 2017 Dec 4.
    Department of Clinical Immunology & Rheumatology, Christian Medical College, Vellore, 632 004, India.
    We evaluated inflammation at the small joints of feet in psoriasis patients without clinical arthritis (PsO) as against clinically overt psoriatic arthritis (PsA) patients, using a low field magnet extremity MRI (eMRI). Patients with psoriasis recruited from dermatology and rheumatology clinics of a tertiary care institution in southern India were divided into PsO and PsA groups. Demographic and physical examination details were recorded. Read More

    Synovial fluid proteomics in the pursuit of arthritis mediators: An evolving field of novel biomarker discovery.
    Crit Rev Clin Lab Sci 2017 Dec 4:1-11. Epub 2017 Dec 4.
    a Department of Laboratory Medicine and Pathobiology , University of Toronto , Toronto , Canada.
    Synovial fluid (SF) is a protein-rich fluid produced into the joint cavity by cells of the synovial membrane. Due to its direct contact with articular cartilage, surfaces of the bone, and the synoviocytes of the inner membrane, it provides a promising reflection of the biochemical state of the joint under varying physiological and pathophysiological conditions. This property of SF has been exploited within numerous studies in search of unique biomarkers of joint pathologies with the ultimate goal of developing minimally invasive clinical assays to detect and/or monitor disease states. Read More

    Focussing on the foot in psoriatic arthritis: pathology and management options.
    Expert Rev Clin Immunol 2017 Dec 9:1-8. Epub 2017 Dec 9.
    a Leeds Institute of Rheumatic and Musculoskeletal Medicine , University of Leeds, Chapel Allerton Hospital , Leeds , UK.
    Introduction: Psoriatic arthritis (PsA) is a heterogeneous chronic inflammatory arthritis characterised by a range of musculoskeletal conditions including enthesitis, dactylitis and synovitis as well as skin and nail manifestations. The foot is a complex mixture of tissues, all of which can be involved in this disease and is frequently the presenting feature. Areas covered: In this under-researched area, articles were reviewed from the authors' publications as well as from other known authors. Read More

    Enthesitis of the hands in psoriatic arthritis: an ultrasonographic perspective.
    Med Ultrason 2017 Nov;19(4):438-443
    Dipartimento di Scienze Cliniche e Biologiche, Università degli Studi di Torino, Turin, Italy.
    Psoriatic arthritis is a systemic inflammatory disease in which enthesitis and dactylitis are two of the main hallmarks of the disease. In the last years, ultrasonography is increasingly playing a key role in the diagnosis of psoriatic arthritis and ultrasonography of the entheses, particularly of the lower limbs, is commonly used to assess patients with that disease. New advancements in ultrasound equipment using high frequencies probes allowed us also to identify and characterize the involvementof the entheses of the hand in psoriatic arthritis, confirming the results of the experimental models of the disease and the theory of the sinovial-entheseal complex, even in small joints. Read More

    Spondyloarthritis features in zymosan-induced SKG mice.
    Joint Bone Spine 2017 Nov 29. Epub 2017 Nov 29.
    Division of Rheumatology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of Korea. Electronic address:
    Objectives: Spondyloarthritis (SpA) encompasses a group of disorders including ankylosing spondylitis, psoriatic arthritis, reactive arthritis, and enteropathic arthritis. SpA pathogenesis is still not well understood. Animal models are important for studying disease mechanisms and identifying new therapeutic agents. Read More

    Characteristic and Outcome of Psoriatic Arthritis Patients with Hyperuricemia.
    J Rheumatol 2017 Dec 1. Epub 2017 Dec 1.
    From the University of Toronto Lupus Clinic, Toronto Western Hospital, Centre for Prognosis Studies in the Rheumatic Diseases, University Health Network, Toronto, Ontario, Canada; Department of Medicine, Taibah University, Medina, Saudi Arabia; Department of Medicine, Division of Rheumatology, University of Toronto, Toronto, Ontario, Canada. R. AlJohani, MD, Clinical and Research Fellow, University of Toronto Lupus Clinic, Toronto Western Hospital, Centre for Prognosis Studies in the Rheumatic Diseases, and Department of Medicine, Taibah University; A. Polachek, MD, Clinical and Research Fellow, University of Toronto Lupus Clinic, Toronto Western Hospital, Centre for Prognosis Studies in the Rheumatic Diseases; J.Y. Ye, MSc, Biostatistician, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital; V. Chandran, MBBS, MD, DM, PhD, Assistant Professor, University of Toronto, Department of Medicine, Division of Rheumatology, University of Toronto, and Co-Director, Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University Health Network; D.D. Gladman, MD, FRCPC, Director, Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, and Senior Scientist, Krembil Research Institute, Toronto Western Hospital, University Health Network. Address correspondence to Dr. D.D. Gladman, University of Toronto Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Krembil Research Institute, University Health Network, 399 Bathurst St. 1E-410B, Toronto, Ontario M5T 2S8, Canada. E-mail: Accepted for publication September 12, 2017.
    Objective: To determine the characteristics of patients with psoriatic arthritis (PsA) who have hyperuricemia (HUC) and their outcomes, especially cardiovascular (CVD) and kidney diseases.

    Methods: Patients have been followed prospectively at the PsA clinic according to a standard protocol at 6- to 12-month intervals. We defined HUC in men > 450 μmol/l or women > 360 μmol/l. Read More

    Relatedness of Antibodies to Peptides Containing Homocitrulline or Citrulline in Patients with Rheumatoid Arthritis.
    J Rheumatol 2017 Dec 1. Epub 2017 Dec 1.
    From the Department of Microbiology and Immunology, and the Department of Medicine/Rheumatology, The University of Western Ontario, London, Ontario, Canada. Funded by a grant (#133685) from The Canadian Institutes of Health Research to E. Cairns, D.A. Bell, and L. Barra. E. Cairns is supported by an award from The Calder Foundation. P. Lac has been supported by a Frederick Banting and Charles Best Canada Graduate Scholarship-Master's from the Canadian Institutes of Health Research. P. Lac, BSc, Department of Microbiology and Immunology, The University of Western Ontario; M. Racapé, PhD, Paris Descartes University and Hôpital Necker, AP-HP, Paris, France; L. Barra, MD, Department of Microbiology and Immunology, and Department of Medicine/ Rheumatology, The University of Western Ontario; D.A. Bell, MD, Department of Medicine/Rheumatology, The University of Western Ontario; E. Cairns, PhD, Department of Microbiology and Immunology, and Department of Medicine/Rheumatology, The University of Western Ontario. Address correspondence to Dr. E. Cairns, Department of Microbiology and Immunology, Schulich School of Medicine and Dentistry, The University of Western Ontario, Dental Sciences Building, Rm. 3014, London, Ontario N6A 5C1, Canada. E-mail: Accepted for publication September 12, 2017.
    Objective: Antibodies that target citrullinated protein/peptide (ACPA) and homocitrullinated/carbamylated protein/peptide (AHCPA) are associated with rheumatoid arthritis (RA). The relationship between ACPA and AHCPA remains unclear. We examined the expression and cross-reactivity of these antibodies using citrulline- and homocitrulline-containing synthetic peptides, CitJED and HomoCitJED, respectively, which have equal numbers of citrulline or homocitrulline residues on the same peptide backbone. Read More

    Modeling of the effects of IL-17 and TNF-α on endothelial cells and thrombus growth.
    C R Biol 2017 Nov - Dec;340(11-12):456-473. Epub 2017 Nov 28.
    Institut Camille-Jordan (ICJ), UMR 5208 CNRS, Université Lyon-1, 69622 Villeurbanne, France; Intitut national de recherche en informatique et automatique (INRIA), Team Dracula, INRIA Lyon La Doua, 69603 Villeurbanne, France; RUDN University, ul. Miklukho-Maklaya 6, 117198 Moscow, Russia.
    Rheumatoid and psoriatic arthritis are chronic inflammatory diseases, with massive increase of cardiovascular events (CVE), and contribution of the cytokines TNF-α and IL-17. Chronic inflammation inside the joint membrane or synovium results from the activation of fibroblasts/synoviocytes, and leads to the release of cytokines from monocytes (Tumor Necrosis Factor or TNF) and from T lymphocytes (Interleukin-17 or IL-17). At the systemic level, the very same cytokines affect endothelial cells and vessel wall. Read More

    Tuberculosis risk in ankylosing spondylitis, other spondyloarthritis and psoriatic arthritis in Sweden: a population-based cohort study.
    Arthritis Care Res (Hoboken) 2017 Dec 1. Epub 2017 Dec 1.
    Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
    Objectives: Rheumatoid arthritis (RA) is a risk factor for tuberculosis (TB), particularly following treatment with biologicals. Since these therapies are increasingly used in ankylosing spondylitis (AS), other types of spondyloarthritis (SpA) and psoriatic arthritis (PsA), we investigated the corresponding TB risks in these patients.

    Methods: We identified individuals with AS/SpA/PsA, and non-AS/SpA/PsA comparators by linking Swedish national Patient, Population, TB and Rheumatology registers, and followed them for TB occurrence. Read More

    Long-term clinical efficacy and safety of secukinumab for Japanese patients with psoriasis: A single-center experience.
    J Dermatol 2017 Nov 30. Epub 2017 Nov 30.
    Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan.
    Secukinumab is a fully human monoclonal antibody that can selectively neutralize interleukin-17A, and its excellent efficacy has been demonstrated in clinical trials for psoriasis. The aim of our study is to assess long-term efficacy and safety of secukinumab for 52 weeks in real-world clinical practise in our facility. A total of 83 patients (71 with psoriasis vulgaris and 12 with psoriatic arthritis) were included, and 49 of them were bio-switched patients. Read More

    Higher Coronary Plaque Burden in Psoriatic Arthritis is Independent of Metabolic Syndrome and Associated with Underlying Disease Severity.
    Arthritis Rheumatol 2017 Nov 28. Epub 2017 Nov 28.
    Department of Rheumatology, St. Vincent's University Hospital, Dublin, Ireland.
    Objectives: To examine the effect of metabolic syndrome (Metsy) and psoriatic disease-related variables on coronary plaque burden in psoriatic arthritis (PsA) patients.

    Methods: 50 PsA patients without symptoms of coronary artery disease (CAD) (25 with Metsy and 25 without (NMetsy)) and 50 age and sex-matched controls underwent 64-slice coronary CT angiography (CCTA). Plaque localisation, segment involvement score (SIS), stenosis severity score (SSS) and total plaque volume (TPV) were calculated. Read More

    GRAPPA-OMERACT consensus-based recommendations and research agenda for use of composite measures and treatment targets in PsA.
    Arthritis Rheumatol 2017 Nov 28. Epub 2017 Nov 28.
    Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.
    Background: Many composite disease activity measures and targets have been developed for psoriatic arthritis (PsA). This GRAPPA-OMERACT work stream aimed to further the development of consensus among physicians and patients.

    Methods: Prior to the meeting, physicians and patients were surveyed on outcome measures. Read More

    CXCL4 is a novel inducer of human Th17 cells and correlates with IL-17 and IL-22 in psoriatic arthritis.
    Eur J Immunol 2017 Nov 29. Epub 2017 Nov 29.
    Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
    CXCL4 regulates multiple facets of the immune response and is highly upregulated in various Th17-associated rheumatic diseases. However, whether CXCL4 plays a direct role in the induction of IL-17 production by human CD4 T cells is currently unclear. Here, we demonstrated that CXCL4 induced human CD4 T cells to secrete IL-17 that co-expressed IFNγ and IL-22, and differentiated naïve CD4 T cells to become Th17-cytokine producing cells. Read More

    The STRIPP questionnaire (Screening Tool for Rheumatologic Investigation in Psoriatic Patients) as a new tool for the diagnosis of early psoriatic arthritis.
    G Ital Dermatol Venereol 2017 Nov 30. Epub 2017 Nov 30.
    Policlinico San Martino-IST, Di.S.Sal. Section of Dermatology, Genoa, Italy.
    Background: Psoriatic arthritis (PsA) is an inflammatory arthritis associated with psoriasis in up to one third of psoriatic patients. Clinically it's characterized from an insidious onset. To help clinicians screen for PsA, several screening tools have been developed. Read More

    Ixekizumab: an anti- IL-17A monoclonal antibody for the treatment of psoriatic arthritis.
    Expert Opin Biol Ther 2017 Nov 29:1-7. Epub 2017 Nov 29.
    a INSERM CIC-1431 , University Hospital of Besançon, Clinical Investigation Center in Biotherapy , Besançon , France.
    Introduction: Psoriatic arthritis (PsA) is an inflammatory rheumatic disease that manifests itself with synovitis, dactylitis, enthesitis and also axial involvement. Interleukin-17A has been identified as a master cytokine in the inflammatory response and pathogenesis of PsA and spondyloarthritis in general. Ixekizumab is a new humanized monoclonal antibody that blocks the biological activity of IL-17A. Read More

    Recommendations for the use of biologics and other novel drugs in the treatment of psoriatic arthritis: 2017 update from the Italian Society of Rheumatology.
    Clin Exp Rheumatol 2017 Nov 28. Epub 2017 Nov 28.
    Dipartimento di Medicina e Scienze per la Salute, Università degli Studi del Molise, Campobasso, Italy.
    Objectives: To update the 2011 Italian Society of Rheumatology (SIR) recommendations for the use of biologics and other novel agents in the treatment of psoriatic arthritis (PsA).

    Methods: To create this new set of recommendations, the SIR "Spondyloartritis and Psoriatic Arthritis study group - A. Spadaro" went through the following steps: literature search, identification of the items of interests for each of the four previously identified clinical domains of PsA and the different treatment phases, achievement of the consensus on all topics, and generation of the recommendations. Read More

    Lessons Learned from Imaging on Enthesitis in Psoriatic Arthritis.
    Isr Med Assoc J 2017 Nov;19(11):708-711
    Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Chapel Allerton.
    Background: Enthesitis is a term that refers to inflammation at tendon, ligament, or joint capsule insertions. The entheses are increasinlgly considered to be the primary site of joint inflammation in the spondyloarthropathies including psoriatic arthritis (PsA). Great advances have occurred in the understanding of enthesopathy, which has resulted in a better understanding of the etiopathogenesis of PsA. Read More

    A resistance exercise program improves functional capacity of patients with psoriatic arthritis: a randomized controlled trial.
    Clin Rheumatol 2017 Nov 28. Epub 2017 Nov 28.
    Rheumatology Division, Universidade Federal de São Paulo, Rua Botucatu, 740, Sao Paulo, SP, CEP 04023-900, Brazil.
    The objective of this study is to assess the effectiveness of resistance training in patients with psoriatic arthritis (PsA). The study is a randomized controlled trial with 41 patients aged between 18 and 65 years with diagnosis of psoriatic arthritis (PsA). The patients were randomized into the following: intervention group (IG) and control group (CG). Read More

    Addressing comorbidities in psoriatic disease.
    Rheumatol Int 2017 Nov 28. Epub 2017 Nov 28.
    University of Toronto, Toronto, Canada.
    Psoriasis and PsA are associated with comorbidities including cardiovascular disease, obesity, metabolic syndrome and depression. The purpose of this study was to examine if patients recognize that they are being monitored for comorbidities associated with their condition, and to determine which physicians are managing these comorbidities. Patients with psoriasis without arthritis (PsC) and patients with PsA were recruited from the University of Toronto Psoriasis Cohort and Psoriatic Arthritis Clinic, respectively. Read More

    Early Recognition and Treatment Heralds Optimal Outcomes: the Benefits of Combined Rheumatology-Dermatology Clinics and Integrative Care of Psoriasis and Psoriatic Arthritis Patients.
    Curr Rheumatol Rep 2017 Nov 20;20(1). Epub 2017 Nov 20.
    Ronald O. Perelman Department of Dermatology, NYU Langone Medical Center, New York University School of Medicine, 240 E. 38th Street, 11th Floor, New York, NY, 10016, USA.
    Purpose Of Review: Diagnosis and treatment of psoriatic arthritis (PsA) can be challenging and require a multidisciplinary approach. This review provides an overview of combined dermatology-rheumatology clinics.

    Recent Findings: Combined dermatology-rheumatology clinics have emerged to optimize integrated care for patients with psoriasis and PsA. Read More

    A Case of Invasive Pneumococcal Infection with Septic Shock and Rare Complications.
    Case Rep Crit Care 2017 18;2017:9503654. Epub 2017 Oct 18.
    Department of Infectious Disease and HIV Medicine, Drexel University College of Medicine, Philadelphia, PA, USA.
    Invasive pneumococcus is a serious illness with potentially devastating outcomes. A 64-year-old female with a medical history of psoriatic arthritis and diabetes was transferred from an outside hospital for ventilator dependent respiratory failure and altered mental status. She initially presented with worsening back pain and was found to have leukocytosis with bandemia and acute renal failure but she was in septic shock upon arrival to our tertiary care center. Read More

    Next generation of biologics for the treatment of Crohn's disease: an evidence-based review on ustekinumab.
    Clin Exp Gastroenterol 2017 15;10:293-301. Epub 2017 Nov 15.
    Department of Gastroenterology, Universitair Ziekenhuis Antwerpen, University of Antwerp, Antwerp, Belgium.
    The limited efficacy of the currently available medical therapies in a proportion of patients with Crohn's disease has led to the research and development of molecules that can block new inflammatory pathways. Ustekinumab is a fully human IgG1 monoclonal antibody which targets the common p40 subunit of the cytokines interleukin-12 as well as interleukin-23. Consequently, the Th1 and Th17 inflammatory responses are inhibited. Read More

    Quantifying bone marrow inflammatory edema in the spine and sacroiliac joints with thresholding.
    BMC Musculoskelet Disord 2017 Nov 28;18(1):497. Epub 2017 Nov 28.
    Department of Circulation and Medical Imaging, Faculty of Medicine and Health Sciences, NTNU - Norwegian University of Science and Technology, 7491 Trondheim, Norway, Trondheim, Norway.
    Background: Psoriatic Arthritis (PsA) is a chronic inflammatory arthritis that develops in patients with psoriasis. Inflammatory edema in the spine may reflect subclinical disease activity and be a predictor of radiographic progression. A semi-quantitative method established by the spondyloarthritis research consortium of Canada (SPARCC) is commonly used to assess the disease activity in MR images of the spine. Read More

    Bariatric Surgery and the Incidence of Psoriasis and Psoriatic Arthritis in the Swedish Obese Subjects Study.
    Obesity (Silver Spring) 2017 Dec;25(12):2068-2073
    Department of Molecular and Clinical Medicine, Institute of Medicine, The Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
    Objective: The aim of this study was to assess the effect of bariatric surgery (vertical gastroplasty, gastric banding, or gastric bypass) compared with usual care on the incidence of psoriasis and psoriatic arthritis (PsA) in the Swedish Obese Subjects study.

    Methods: This report includes 1,991 subjects who underwent bariatric surgery and 2,018 controls with obesity from the SOS study; none of them had psoriasis or PsA at baseline. Information about psoriasis and PsA diagnosis was retrieved through the Swedish National Patient Register and questionnaires. Read More

    Reprint of "Anti-therapeutic antibodies and their clinical impact in patients treated with the TNF antagonist adalimumab".
    Cytokine 2018 Jan 23;101:70-77. Epub 2017 Nov 23.
    Biotherapeutics Group, Cytokines and Growth Factor Section, National Institute for Biological Standards and Control, Medicines and Healthcare products Regulatory Agency, Blanche Lane, Potters Bar, Hertfordshire EN6 3QG, United Kingdom.
    Patients treated with the TNF antagonist adalimumab develop anti-therapeutic antibodies (ATA), the prevalence of which varies depending on the assay used. Most assays are compromised due to the presence of adalimumab in the clinical samples. Our objective was to develop an antibody assay, applicable for clinical testing, which overcomes the limitation of therapeutic interference and to further determine the relationship between ATA development, adalimumab levels and disease activity in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) or ankylosing spondylitis (AS). Read More

    [Uveitis-associated HLA class 1 histocompatibility antigens].
    Vestn Oftalmol 2017 ;133(5):11-15
    Research Institute of Eye Disease, 11A, B Rossolimo St., Moscow, Russian Federation, 119021.
    Aim: to evaluate the diagnostic and prognostic significance of HLA class 1 histocompatibility antigens in the development of anterior uveitis.

    Material And Methods: A total of 137 patients with anterior uveitis followed up at the Research Institute of Eye Diseases in 2009-2016 were tested for HLA antigens (A and B loci). The average patient's age was 29±12. Read More

    Mapping Quality of Life (EQ-5D) from DAPsA, Clinical DAPsA and HAQ in Psoriatic Arthritis.
    Patient 2017 Nov 21. Epub 2017 Nov 21.
    Institute of Health Economics and Technology Assessment, Vaclavska 316/12, 12000, Prague 2, Czech Republic.
    Background: Clinical trials and observational studies lacking measures of health-related quality of life (QoL) are often inapplicable when conducting cost-effectiveness analyses using quality-adjusted life-years (QALYs). The only solution is to map QoL ex post from additionally collected clinical outcomes and generic QoL instruments. Nonetheless, mapping studies are absent in psoriatic arthritis (PsA). Read More

    CD4 T-Cell Dysregulation in Psoriatic Arthritis Reveals a Regulatory Role for IL-22.
    Front Immunol 2017 27;8:1403. Epub 2017 Oct 27.
    Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom.
    Dysregulation of interleukin-22 (IL-22) has been associated with autoimmune diseases but divergent effects upon inflammation have hampered efforts to define its contribution to pathogenesis. Here, we examined the role of IL-22 in patients with psoriatic arthritis (PsA). In the peripheral blood of PsA patients, there was a decrease in IL-22+CD4+ T cells compared with healthy controls resulting in a heightened CD4+ IFNγ+/IL-22+ ratio accompanied by diminished CCR6 expression. Read More

    Increased risk of periodontitis in patients with psoriatic disease: a nationwide population-based retrospective cohort study.
    PeerJ 2017 16;5:e4064. Epub 2017 Nov 16.
    Department of Periodontics, Chung Shan Medical University Hospital, Taichung, Taiwan.
    Aims: Periodontitis and psoriatic disease, including psoriasis (PS) and psoriatic arthritis (PsA), share the common risk factors and co-morbidities. However, the risk of periodontitis in patients with psoriatic disease still needs further investigation. This study was a nationwide population-based retrospective cohort study assessing the risk of periodontitis from psoriatic disease exposure. Read More

    Enthesitis: from pathophysiology to treatment.
    Nat Rev Rheumatol 2017 Nov;13(12):731-741
    Section of Musculoskeletal Diseases, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and Chapel Allerton Hospital, Chapeltown Road, Leeds, West Yorkshire LS7 4SA, UK.
    Entheses are the insertion sites of tendons and ligaments to the bone surface and are essential structures for locomotion. Inflammation of the entheses (enthesitis) is a key feature of psoriatic arthritis and spondyloarthritis. To date, our conceptual understanding of enthesitis remains limited. Read More

    Treatment Strategies for Psoriatic Arthritis.
    Joint Bone Spine 2017 Nov 16. Epub 2017 Nov 16.
    Service de Rhumatologie, Hôpital Henri Mondor, APHP, 94000 Créteil, France; EA 7379, Epiderm E, Université Paris Est Créteil, 94010 Créteil, France. Electronic address:
    The therapeutic management of psoriatic arthritis has seen major changes over the last few years, as illustrated by the recent updates of the GRAPPA and EULAR recommendations. These changes were driven by new studies establishing important benefits from early management and tight control of disease activity. The concepts underlying the treatment of psoriatic arthritis must be reappraised in the light of these new data. Read More

    Switching from originator infliximab to biosimilar CT-P13 in real-life: the weight of patient acceptance.
    Joint Bone Spine 2017 Nov 14. Epub 2017 Nov 14.
    Centre Hospitalier Universitaire de Bordeaux, Service de Rhumatologie, Place Amélie Raba Léon, 33076 Bordeaux, France; Université de Bordeaux, 146 rue Léo Saignat, 33076 Bordeaux, France. Electronic address:
    Objective: To explore acceptance and retention rate of biosimilar CT-P13 after switching from originator infliximab (OI) in patients with various rheumatic diseases.

    Methods: Patients with stable rheumatoid arthritis (RA), ankylosing spondylitis (AS) or psoriatic arthritis (PsA) under OI were proposed to switch to CT-P13 at the same regimen. A prospective cohort of infliximab-naïve patients beginning CT-P13 and a retrospective cohort of patients treated with OI were used as controls. Read More

    Interleukin-17 Alters the Biology of Many Cell Types Involved in the Genesis of Psoriasis, Systemic Inflammation, and Associated Comorbidities.
    Exp Dermatol 2017 Nov 20. Epub 2017 Nov 20.
    Laboratory of Investigative Dermatology, The Rockefeller University, New York, NY, USA.
    Psoriasis is a chronic, immune-mediated, systemic inflammatory disease that is defined by a characteristic skin reaction produced when elevated levels of inflammatory cytokines such as interleukin (IL)-17 alter the growth and differentiation of skin cells. The pathogenesis of comorbid conditions associated with psoriasis, including psoriatic arthritis, cardiovascular disease, obesity, metabolic syndrome, liver disorders, renal disease, and depression are also largely affected by inflammation. In this review, we examine the effect of IL-17 on the inflammatory pathways in a variety of different cell types, including keratinocytes, as well as epithelial cells of the colon, kidney, gut, and liver. Read More

    Risk of active tuberculosis in patients with inflammatory arthritis receiving TNF inhibitors: a look beyond the baseline tuberculosis screening protocol.
    Clin Rheumatol 2017 Nov 17. Epub 2017 Nov 17.
    Department of Internal Medicine and Rheumatology, Cantacuzino Clinical Hospital, Ion Movila 5-7, 020475, Bucharest, Romania.
    Tuberculosis (TB) is a major concern in patients receiving TNF inhibitors (TNFi). This study aimed to assess the incidence of active TB and the efficacy of TB prevention measures used over the years, and to determine risk factors for developing TB, in a single-centre cohort of patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) receiving TNFi. Data of all patients in whom treatment with TNFi was initiated in our rheumatology clinic until December 1st 2014 have been retrospectively analysed. Read More

    Gastrointestinal and Hepatic Disease in Spondyloarthritis.
    Rheum Dis Clin North Am 2018 Feb;44(1):153-164
    Department of Medicine, University of Colorado School of Medicine, 1775 Aurora Court, Campus Box B115, Aurora, CO 80045, USA.
    The association of inflammatory arthritis with intestinal pathology extends back more than 100 years. This association is now supported by epidemiologic studies demonstrating an elevated prevalence of inflammatory bowel disease in spondyloarthritis and vice versa, compared with the general population. Genetic and intestinal microbiome studies have further linked these diseases. Read More

    Cardiovascular Risk in Psoriasis: Current State of the Art.
    Curr Vasc Pharmacol 2017 11 16. Epub 2017 Nov 16.
    Dept. of Clinical and Experimental Medicine, Section of Cardiology, University of Messina, Italy
    Psoriasis (Pso) is a chronic inflammatory immune-mediated skin disease associated with several comorbidities. Despite the growing number of studies providing evidence for the link between Pso and cardiovascular (CV) disorders, there are still many unsolved questions, dealing with the role of the skin disease as an independent risk factor for CV events, the influence of Pso severity and duration on CV damage, the presence of psoriatic arthritis (PsA) as a predictor of increased CV mortality and morbidity and the detection of reliable clinical, laboratory and/or instrumental parameters to stratify CV risk in psoriatic patients. Moreover, it remains to clarify if the early treatment of the dermatosis may lower CV risk. Read More

    The role of IL-23 receptor signaling in inflammation-mediated erosive autoimmune arthritis and bone remodeling.
    Eur J Immunol 2017 Nov 17. Epub 2017 Nov 17.
    Department of Rheumatology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
    The IL-23/Th17 axis has been implicated in the development of autoimmune diseases, such as rheumatoid arthritis (RA) and psoriatic arthritis (PsA). RA and PsA are heterogeneous diseases with substantial burden on patients. Increasing evidence suggests that the IL-23 signaling pathway may be involved in the development of autoimmunity and erosive joint damage. Read More

    A validation study of the Simple Psoriatic Arthritis Screening (SiPAS) questionnaire to screen psoriasis patients for psoriatic arthritis.
    Clin Exp Rheumatol 2017 Nov 16. Epub 2017 Nov 16.
    Dermatological Clinic, Università Politecnica delle Marche, Ancona, Italy.
    Objectives: To validate in a multicentric cohort of patients a self-administered PsA screening tool, called Simple Psoriatic Arthritis Screening (SiPAS) questionnaire, to screen psoriasis patients for signs and symptoms of PsA.

    Methods: The SiPAS questionnaire was validated in a multicentric Italian cohort of psoriasis patients referred to two rheumatological centres.

    Results: A total of 202 psoriasis patients were screened with SiPAS in the validation study. Read More

    Th17 gene expression in psoriatic arthritis synovial fluid and peripheral blood compared to osteoarthritis and cutaneous psoriasis.
    Clin Exp Rheumatol 2017 Nov 9. Epub 2017 Nov 9.
    University of Toronto Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Research Institute; Division of Rheumatology, Dept. of Medicine; Institute of Medical Science, University of Toronto, Canada.
    Objectives: The IL-23/IL-17 axis is central to the pathogenesis of psoriatic arthritis (PsA). We aimed to identify Th17 signalling genes that are dysregulated in synovial fluid of PsA compared to osteoarthritis (OA) patients and to determine if differences in peripheral blood can distinguish PsA from psoriasis patients and controls.

    Methods: Synovial fluid cells (SFCs) from 14 PsA and 9 OA patients were obtained and stored in TRIzol reagent. Read More

    High 3-year golimumab survival in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: real world data from 328 patients.
    Clin Exp Rheumatol 2017 Nov 9. Epub 2017 Nov 9.
    Joint Rheumatology Program, Clinical Immunology-Rheumatology Unit, 2nd Department of Medicine and Laboratory, Hippokration General Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
    Objectives: Our primary objective was to study the long-term survival on drug (SOD) of patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) treated with golimumab (GLM) in real life settings.

    Methods: This was a retrospective, observational study of all patients treated with GLM in 4 Academic Centres in Greece during a 4-year period (09/2010-06/2014). SOD was analysed using Kaplan-Meier survival analysis, while Cox regression analysis estimating hazard ratios (HRs) for different baseline variables associated with drug discontinuation was performed for each disease. Read More

    1 OF 171